09 jan: Ambu A/S: Ambu får FDA-godkendelse på engangs-koloskop i USA før ..
10 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 86,9 kr. pr. a..
09-01-2018 20:58:38

Major Shareholder Announcement

Company Announcement

  • Major shareholder announcement for Genmab A/S

Copenhagen, Denmark; January 9, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29 of the Danish Securities Trading Act that Artisan Partners Limited Partnership has informed us that, as of January 5, 2018, Artisan Partners Limited Partnership has increased their indirect ownership in Genmab A/S to 3,081,731 shares, which amounts to 5.04% of the share capital and voting rights in Genmab A/S.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com. 

Contact:         

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 01

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 maj
 
Hej,   Jeg har været herinde i dette forum siden 2010, og har fulgt mange debatører, men en af dem s..
28
17 maj
PNDORA
Jeg personligt mener at en stor del af skribenterne her på forum og markedet som helhed overreagerer..
17
16 maj
PNDORA
Pandora dykkede fordi der manglede 60 millioner i omsætning ud af 1.500 millioner. Det er jo helt gr..
16
19 maj
PNDORA
Pandora realiserede i Q1 2018 en omsætning, som var 44 mDKK lavere end 1Q 2017, såfremt valutakurser..
14
17 maj
NOVO-B
Trump fik fortalt at PBM'ernes rabatsystem er taget for fremskaffelse af lavere priser til patienter..
14
18 maj
DANSKE
Kongsmart, Jensen og Pedersen var de 3 sidste kandidater til en højt betroet post i banken. De mangl..
13
15 maj
VELO
Har lyttet til det nu. Ikke så meget nyt, men bider mærke i, at Envarsus bliver mere og mere en fast..
13
14 maj
VELO
Nu begynder Veloxis at levere varen. Det er klart, at med en vækst 142% i omsætning i forhold til Q1..
13
14 maj
NOVO-B
Nu vil jeg ikke bruge meget tid på dit "Sikken dog noget sludder"  udover, at det er klart, at du ik..
13
19 maj
PNDORA
Når nu det kan være så svært, at tolke shortere, og andre på markedet, så kan det være en god ide, a..
12

Møns Bank Q1: Lille løft på bundlinjen

18-05-2018 13:48:49
Møns Bank kom ud af første kvartal med en stærkere bundlinje, men i store træk resultater, der minder meget om samme periode året før. Forventningerne om et overskud før skat på 20-30 mio. kr. i hele 2018 fastholdes.I første kvartal fik Møns Bank et overskud før skat på 10,7 mio. kr. mod 10 mio. kr. i samme periode sidste år. Dermed er banken allerede over halvvejs i forhold til at nå den nedre en..

Rockwool/CEO: Gode markeder, tiltag og let sammenligning bag fremgang

18-05-2018 09:22:44
Rockwool er kommet flyvende fra start i 2018 og kan fremvise stærk vækst på alle hovedpunkter i det regnskab for første kvartal, som isoleringskoncernen offentliggjorde fredag. Lette sammenligningstal bidrager til billedet, men derudover spiller stærke markeder, prisjusteringer og effektivitesforbedringer ind, siger Rockwools administrerende direktør, Jens Birgersson, i et interview med Ritzau Fin..

Aktier/tendens: Mærsk fortsætter i negativ fokus på ellers positiv dag

18-05-2018 08:26:19
A.P. Møller-Mærsk fik en grum dag torsdag med store fald i aktiekurserne - og det ser ikke ud til, at stormen er drevet over for denne gang for koncernen. Med avisoverskrifter som "Søren Skous nødplan får hårde odds", "Mærsk skuffer fælt" og "Investorerne er ikke begejstrede for Mærsks bud på fremtiden" kan fokus endnu en gang være rettet mod aktierne i koncernen, når handlen starter fredag morgen..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. maj 2018 02:30:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180515.2 - EUROWEB5 - 2018-05-22 02:30:22 - 2018-05-22 02:30:22 - 1 - Website: OKAY